Israel Englander Arcus Biosciences, Inc. Call Options Transaction History

Millennium Management LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$14.59 - $18.48 $5,836 - $7,392	400 Added 0.8%	50,400 $767,000
Q1 2024 May 15, 2024	BUY	$14.83 - $20.18 $741,500 - $1.01 Million	50,000 New	50,000 $944,000
Q2 2023 Aug 14, 2023	BUY	$16.97 - $22.03 $1.62 Million - $2.1 Million	95,300 Added 86.64%	205,300 $4.17 Million
Q4 2022 Feb 14, 2023	BUY	$19.7 - $35.71 $1.16 Million - $2.11 Million	59,000 Added 115.69%	110,000 $2.28 Million
Q3 2022 Nov 14, 2022	SELL	$23.23 - $30.07 $1.49 Million - $1.93 Million	-64,300 Reduced 55.77%	51,000 $1.33 Million

207

49M

173K

151K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.19B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.